# GRIN Therapeutics > GRIN Therapeutics, Inc. is a clinical-stage biotechnology company developing precision therapeutics > for pediatric neurodevelopmental disorders caused by NMDA receptor dysfunction. It is an affiliate > of Neurvati Neurosciences, a Blackstone Life Sciences portfolio company. Its lead investigational > asset is radiprodil, an orally bioavailable selective negative allosteric modulator of the GluN2B > subunit of the NMDA receptor, in development for GRIN-related neurodevelopmental disorder > (GRIN-NDD), tuberous sclerosis complex (TSC) and focal cortical dysplasia (FCD) type II. GRIN Therapeutics runs no developer program. It publishes no product API, no developer portal, no API documentation, no SDKs, no CLI, no MCP server, no A2A agent card, no status page and no /.well-known/ discovery surface. The only machine-readable surface reachable without credentials is the WordPress REST content API behind grintherapeutics.com, which serves the corporate site. This file was generated by API Evangelist from the public catalog profile at https://github.com/api-evangelist/grin-therapeutics — it is not published by GRIN Therapeutics. Generated: 2026-08-04 Method: generated (no /llms.txt is published at grintherapeutics.com — probed 2026-08-04, HTTP 404) ## Company - [GRIN Therapeutics](https://grintherapeutics.com/): Corporate home. - [About GRIN Therapeutics](https://grintherapeutics.com/about-grin-therapeutics/): Mission, founding story, leadership team and board of directors. - [Our Science](https://grintherapeutics.com/our-science/): Radiprodil mechanism of action and the clinical development programme. - [Disease State](https://grintherapeutics.com/disease-state/): GRIN-NDD, TSC and FCD type II background. - [Resources for patients and caregivers](https://grintherapeutics.com/resources-for-patients-and-caregivers/): Patient and caregiver resources. - [News](https://grintherapeutics.com/news/): Press releases and corporate events. Hand-authored page — not a dated feed. - [Careers](https://grintherapeutics.com/careers/): Open roles. - [Working with Grin Therapeutics](https://grintherapeutics.com/contact/): Contact forms for patients, clinical research, partnerships, careers and general inquiries. Phone +1-877-225-0014. - [Neurvati Neurosciences](https://neurvati.com/): Parent affiliate, a Blackstone Life Sciences portfolio company. ## Science and pipeline - Lead asset: radiprodil — orally bioavailable, selective negative allosteric modulator of the NMDA receptor GluN2B subunit. - Indications: GRIN-NDD (gain-of-function variants in GRIN1, GRIN2A, GRIN2B, GRIN2D), tuberous sclerosis complex, focal cortical dysplasia type II. - Honeycomb — Phase 1b/2a in GRIN-NDD (gain-of-function). Complete; topline data Q3 2024. - Beeline — global Phase 3 registrational trial in GRIN-NDD (gain-of-function). Enrolling in the US, UK and Europe. - Astroscape — Phase 1b/2a in TSC and FCD type II. Enrolling. - GRIN-NDD Natural History Study — observational. Enrolling. - Designations: FDA Breakthrough Therapy, FDA Orphan Drug, FDA Rare Pediatric Disease, EMA PRIME, EMA Orphan Drug. - Partnership: exclusive collaboration with Angelini Pharma (May 2025) to develop and commercialise radiprodil outside North America. ## APIs - [GRIN Therapeutics Content API](https://grintherapeutics.com/wp-json/): The anonymously readable WordPress REST content API behind grintherapeutics.com. Read-only for anonymous callers. Ten published pages, a 174-item media library, taxonomies, public author records, cross-content search and an oEmbed 1.0 provider endpoint. The `posts` collection is registered but empty. - [WordPress REST API handbook](https://developer.wordpress.org/rest-api/): The upstream reference that defines the wp/v2 contract. GRIN Therapeutics publishes no API documentation of its own. ## Specs and artifacts - [OpenAPI 3.1 (derived)](https://raw.githubusercontent.com/api-evangelist/grin-therapeutics/refs/heads/main/openapi/grin-therapeutics-content-openapi.yml): 19 operations derived from the live route index and verified against anonymous responses. - [APIs.json](https://raw.githubusercontent.com/api-evangelist/grin-therapeutics/refs/heads/main/apis.yml): The full catalog profile. - [Authentication](https://raw.githubusercontent.com/api-evangelist/grin-therapeutics/refs/heads/main/authentication/grin-therapeutics-authentication.yml): Anonymous read; application passwords and cookie+nonce gate the rest. - [Conventions](https://raw.githubusercontent.com/api-evangelist/grin-therapeutics/refs/heads/main/conventions/grin-therapeutics-conventions.yml): Pagination, field selection, embedding, caching, error envelope. - [Error catalog](https://raw.githubusercontent.com/api-evangelist/grin-therapeutics/refs/heads/main/errors/grin-therapeutics-problem-types.yml): Live-observed error responses. Not RFC 9457. - [Data model](https://raw.githubusercontent.com/api-evangelist/grin-therapeutics/refs/heads/main/data-model/grin-therapeutics-data-model.yml): Entity-relationship graph. - [Conformance](https://raw.githubusercontent.com/api-evangelist/grin-therapeutics/refs/heads/main/conformance/grin-therapeutics-conformance.yml): Standards this surface does and does not meet. - [Lifecycle](https://raw.githubusercontent.com/api-evangelist/grin-therapeutics/refs/heads/main/lifecycle/grin-therapeutics-lifecycle.yml): No versioning policy, no deprecation policy, no SLA, no status page. - [Well-known](https://raw.githubusercontent.com/api-evangelist/grin-therapeutics/refs/heads/main/well-known/grin-therapeutics-well-known.yml): Every /.well-known/ path probed, all 404. - [Domain security](https://raw.githubusercontent.com/api-evangelist/grin-therapeutics/refs/heads/main/security/grin-therapeutics-domain-security.yml): TLS 1.3, HSTS max-age 300, SPF and DMARC (quarantine) present, no DNSSEC, no CAA. - [Agent skills](https://raw.githubusercontent.com/api-evangelist/grin-therapeutics/refs/heads/main/skills/_index.yml): Packaged operating instructions for the content API. ## Not published - No OpenAPI, AsyncAPI, JSON Schema or GraphQL schema published by GRIN Therapeutics. - No SDKs or client libraries on npm, PyPI or any registry; no GitHub organization. - No CLI, no sandbox, no Postman collection, no embedded components. - No MCP server. The site registers the WordPress Abilities API (`wp-abilities/v1`) but every route under it returns 401 to anonymous callers, so no agent capability is exposed. - No A2A agent card at `/.well-known/agent-card.json` or `/.well-known/agent.json` (both 404). - No security.txt, no vulnerability disclosure policy, no bug bounty, no trust center, no named certifications. - No pricing, sign-up, terms of service, rate-limit policy or webhooks — there is no developer product to price or subscribe to.